Management (3rd rendition) has not done well thus far (telling story, executing, creating value, strengthening balance sheet...)
Assets/Valuation: I think they have a good mix of assets priced as cheaply as any gene therapy company one could find probably because of a management/financing discount. Their MPS IIIA + EB get all the publicity but the jewel could turn out to be their CF program and perhaps some differentiated vectors from their library.
They could announce a deal to relieve some of the financings overhang. The chairman owns a ton of shares or I'd be more worried about one of those 100% dilutive toxic financings though I guesss that can't be totally ruled out.
Any specific questions? I'm not on I-hub too much these days you could try ask on Twitter for a quicker reply (@MauriceOnTW).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.